Showing results (41-50 of 49) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Frontiers in Immunology|August 7, 2023
Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRβ complex in hepatocellular carcinomaJieying Yang, Zhixing Guo, Mengjia Song, et al.Clinical & Translational Immunology|October 19, 2020
Severe delayed pulmonary toxicity following PD-L1-specific CAR-T cell therapy for non-small cell lung cancerHeping Liu, Yuxiang Ma, Chaopin Yang, et al.Cell Death & Disease|November 19, 2021
Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatinFengze Sun, Yuanyuan Liu, Tingting Gong, et al.Journal for Immunotherapy of Cancer|March 12, 2022
CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotypeHan Li, Fan Luo, Xingyu Jiang, et al.Journal for Immunotherapy of Cancer|June 17, 2024
EBV promotes TCR-T-cell therapy resistance by inducing CD163+M2 macrophage polarization and MMP9 secretionYuanyuan Chen, Dijun Ouyang, Yan Wang, et al.Cell Reports. Medicine|August 16, 2023
Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcomaQiuzhong Pan, Desheng Weng, Jiayong Liu, et al.BMC Medicine|August 27, 2023
Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinomaChaopin Yang, Jinqi You, Qiuzhong Pan, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 21, 2025
The CXCL10-CXCR3 Axis Induces Tumor-Associated Neutrophils to Interfere with CTLs-Mediated Antitumor Activity in EBV-Associated Epithelial CancersDijun Ouyang, Tong Xiang, Yuanyuan Chen, et al.European Journal of Cancer (Oxford, England : 1990)|January 18, 2024
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trialPanpan Zhang, Si Shi, Jianming Xu, et al.Pageof 5